J Physiol Editor in Chief
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Physiol Volume 586, Number 11, 2743-2752, June 1, 2008 DOI: 10.1113/jphysiol.2008.153346
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
586/11/2743    most recent
jphysiol.2008.153346v1
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Xie, A.
Right arrow Articles by Qian, H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xie, A.
Right arrow Articles by Qian, H.
Related Collections
Right arrow Neuroscience

NEUROSCIENCE

Cyclothiazide: a subunit-specific inhibitor of GABAC receptors

An Xie1, Xiangqian Song1, Harris Ripps1,3,4 and Haohua Qian1,2,4

1 Departments of Ophthalmology and Visual Sciences
2 Biological Sciences
3 Anatomy and Cell Biology
4 Physiology & Biophysics, University of Illinois College of Medicine, 1855 West Taylor Street, Chicago, IL 60612, USA

We tested the effects of cyclothiazide (CTZ), an agent used to block desensitization of AMPA-type glutamate receptors, on heterologously expressed GABAC receptors formed by homomeric {rho} subunits. CTZ inhibition of GABAC receptors was subunit specific; it produced a dose-dependent reduction of the GABA-elicited current on homomeric {rho}2 receptors with an IC50 of about 12 µM, but had no significant effect on homomeric {rho}1 receptors. This differential sensitivity was attributable to a single amino acid located on the second transmembrane domain of the {rho} subunits. Mutating the residue at this position from serine to proline on the {rho}2 subunit eliminated CTZ sensitivity, whereas switching proline to serine on the {rho}1 subunit made the receptor CTZ sensitive. The inhibitory properties of CTZ were consistent with its action as a channel blocker on the receptors formed by {rho}2 subunits. The effect showed a small degree of voltage dependence, and was due mainly to a non-competitive mechanism that reduced the maximum response elicited by GABA. In addition, the prominent membrane current rebound when co-application of GABA and CTZ was terminated suggests that the binding site for CTZ on the GABAC receptor is distinct from that for GABA, and that CTZ acts as a non-competitive antagonist on the GABAC receptor. CTZ inhibited the open channel of the GABAC receptor with a time constant of about 0.4 s, but the kinetics were ~10-fold slower when GABA is absent. The ability of CTZ to interact with various types of neurotransmitter receptors indicates that the drug has multiple actions in the CNS.

(Received 4 March 2008; accepted after revision 10 April 2008; first published online 17 April 2008)
Corresponding author H. Qian: Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, 1855 W. Taylor Street, Chicago, IL 60612, USA. Email: hqian{at}uic.edu


All authors contributed equally to this work.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 The Physiological Society.